Royalty Pharma PLC RPRX
We take great care to ensure that the data presented and summarized in this overview for Royalty Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPRX
View all-
Morgan Stanley New York, NY41.1MShares$1.26 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$1.16 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$708 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$496 Million0.35% of portfolio
-
Viking Global Investors LP12.1MShares$372 Million1.32% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.9MShares$366 Million0.62% of portfolio
-
Swedbank Ab Stockholm, V711MShares$339 Million0.4% of portfolio
-
State Street Corp Boston, MA9.52MShares$293 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA7.27MShares$223 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.34MShares$134 Million0.06% of portfolio
Latest Institutional Activity in RPRX
Top Purchases
Top Sells
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Transactions at RPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,503
+2.64%
|
$36,072
$24.94 P/Share
|
|
Dec 31
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,503
+2.39%
|
$36,072
$24.94 P/Share
|
|
Sep 30
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,342
+2.42%
|
$36,234
$27.92 P/Share
|
|
Sep 30
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,342
+2.2%
|
$36,234
$27.92 P/Share
|
|
Jun 28
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,399
+2.34%
|
$36,374
$26.8 P/Share
|
|
Jun 28
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,399
+2.59%
|
$36,374
$26.8 P/Share
|
|
Jun 07
2024
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+11.19%
|
-
|
|
Jun 07
2024
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+26.55%
|
-
|
|
Jun 07
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+16.74%
|
-
|
|
Jun 07
2024
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+11.19%
|
-
|
|
Jun 07
2024
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+17.6%
|
-
|
|
Jun 07
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+15.35%
|
-
|
|
Jun 07
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+14.01%
|
-
|
|
May 13
2024
|
Christopher Hite EVP & Vice Chairman |
BUY
Conversion of derivative security
|
Indirect |
300,000
+44.78%
|
-
|
|
Mar 28
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,240
+2.87%
|
$37,200
$30.23 P/Share
|
|
Mar 28
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,240
+2.53%
|
$37,200
$30.23 P/Share
|
|
Feb 20
2024
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
300,000
+48.38%
|
-
|
|
Jan 04
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
35,702
-63.98%
|
$963,954
$27.55 P/Share
|
|
Jan 03
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
199,098
-78.11%
|
$5,375,646
$27.79 P/Share
|
|
Jan 02
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
235,200
-47.99%
|
$6,585,600
$28.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 76K shares |
|---|---|
| Conversion of derivative security | 600K shares |